The effect of the plasticizer diethylhexyl phthalate on transport activity and expression of P-glycoprotein in parental and doxo-resistant human sarcoma cell lines

Journal of Biological Regulators and Homeostatic Agents

Volumn 25, Issue 2, 2011, Pages 203-211

  Angelini, Antonio ^a   Centurione, L ^a   Sancilio, S ^a   Castellani, M L ^a   Conti, P ^a   Di Ilio, C ^a   Porreca, E ^a   Cuccurullo, F ^a   Di Pietro, R ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

DEHP; Doxo; MES SA; MES SA Dx5; P glycoprotein

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; PHTHALIC ACID BIS(2 ETHYLHEXYL) ESTER; VERAPAMIL; ANTINEOPLASTIC AGENT; PLASTICIZER;

ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; PROTEIN EXPRESSION; SARCOMA CELL; ACTIVE TRANSPORT; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; SARCOMA; TUMOR CELL LINE; UTERUS CANCER;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL TRANSPORT, ACTIVE; CELL LINE, TUMOR; DIETHYLHEXYL PHTHALATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; P-GLYCOPROTEIN; PLASTICIZERS; SARCOMA; UTERINE NEOPLASMS;

EID: 80052903936     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Ling V. Multidrug resistance: molecular mechanism and clinical relevance. Cancer Chemother Pharmacol 1997; 40:3-8.
2. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455:152-62.
3. Pastan I, Gottesman MM. Multiple-drug resistance in human cancer. N Engl J Med 1987; 316:1388-93. (Pubitemid 17079683)
4. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62:385-27.
5. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1991; 39:361-98.
6. Nooter K, Stoter G. Molecular mechanism of multidrug resistance in cancer chemotherapy. Pathol Res Pract 1996; 192:768-80. (Pubitemid 26302251)
7. Seeber S, Asieka R, Schmidt CG, Achterrath W, Crooke GT. In vivo resistance towards anthracycline, etoposide and cisdiaminedichloroplatinum. Cancer Res 1982; 42:4719-25. (Pubitemid 13205979)
8. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002; 53:615-27. (Pubitemid 34177898)
9. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992; 80:2735-9.
10. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2:48-58. (Pubitemid 37328807)
11. Endicott JA, Ling VZ. The biochemistry of P-glycoprotein mediated multidrug resistance. Annu Rev Biochem 1989; 58:137-71. (Pubitemid 19172967)
12. Higgins CF. ABC transporters: from microorganism to man. Annu Rev Cell Biol 1992; 8:67-113.
13. Sauna ZE, Smith MM, Muller M, Kerr KM, Ambudkar SV. The mechanism of action of multidrug-resistance-linked P-glycoprotein. J Bioenerg Biomembr 2001; 33:481-91. (Pubitemid 34052574)
14. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000; 11:265-83.
15. Borowski E, Bontemps-Gracz MM, Piwkowska A. Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells. Acta Biochim Pol 2005; 52:609-27. (Pubitemid 41571706)
16. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 2003; 10:159-65. (Pubitemid 36437822)
17. Sarkadi B, Müller M. Search for specific inhibitors of multidrug resistance in cancer. Semin Cancer Biol 1997; 8:171-82. (Pubitemid 28041014)
18. Twentymann PR, Bleehen NM. Resistance modification by PSC 833, a novel non-immunosuppressive cyclosporine. Eur J Cancer 1991; 7:1639-42.
19. Green LJ, Marder P, Slapack CA. Modulation by LY335979 of P-glycoprotein function in multidrug-resistant cell lines and human natural killer cells. Biochem Pharmacol 2001; 61:1393-99. (Pubitemid 32452355)
20. Bardelmeijer HA, Beijnen JH, Brouwer KR, Rosing H, Nooijen WJ, Shellens JH, Van Tellingen O. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin Cancer Res 2000; 6:4416-21.
21. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 1997; 40:13-19.
22. Angelini A, Di Ilio C, Castellani ML, Conti P, Cuccurullo F. Modulation of multidrug resistance P-glycoprotein activity by flavonoids and honokiol in human doxorubicin-resistant sarcoma cells (MES-SA/Dx5): implications for natural sedatives as chemosensitizing agents in cancer therapy. J Biol Regul Homeost Agents 2010; 24:197-05.
23. Wesolowska O, Paprocka M, Koziak J, Motohashi N, Dus D, Michalak K. Human sarcoma cell lines MES-SA and MES-SA/Dx5 as a model for multidrug resistance modulators screening. Anticancer Res 2005;25:383-89. (Pubitemid 40470134)
24. Harker WG, Sikic BI. Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. Cancer Res 1985; 45:4091-096. (Pubitemid 16224856)
25. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 2005; 25:383-89.
26. Hongo T, Fujii Y, Igarashi Y. An in vitro chemosensitivity test for the screening of anti cancer drugs in childhood leukaemia. Cancer 1990; 65:1263-272. (Pubitemid 20097146)
27. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J Immunol Methods 1983; 65:55-63. (Pubitemid 14203433)
28. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 2003; 10:159-65. (Pubitemid 36437822)
29. Inoue K, Kawaguchi M, Yamanaka R, Higuchi T, Ito R, Saito K, Nakazawa H. Evaluation and analysis of exposure levels of di(2-ethylhexyl) phthalate from blood bags. Clin Chim Acta 2005; 358:159-66. (Pubitemid 40966644)
30. Rael LT, Bar-Or R, Ambruso DR, Mains CW, Slone DS, Craun ML, Bar-Or D. Phthalate esters used as plasticizers in packed red blood cell storage bags may lead to progressive toxin rxposure and the release of pro-inflamatory cytokines. Oxid Med Cell Longev 2009; 2:166-71.
31. Buchta C, Bittner C, Hocker P, Macher M, Rainer S, Seger C, Dettke M. Donor exposure to the plasticizer di(2-ethylhexyl)phthalate during plateletpheresis. Hemapheresis 2003; 43:1115-20. (Pubitemid 37022372)
32. Buchta C, Bittner C, Heinzl H, Hocker P, Macher M, Mayerhofer M, Schmid R, Seger C, Dettke M. Transfusion-related exposure to the plasticizer di(2-ethylhexyl)phthalate in the patients receiving plateletpheresis concentrates. Transfusion Complications 2005; 45:798-802. (Pubitemid 40656395)
33. Demore B, Vigneron J, Perrin A, Hoffman A, Hoffman M. Leaching of Diethylhexyl Phthalate from Polyvinylchloride bags into intravenous etoposide solution. J Clin Pharm Therapeutics 2002; 27:139-42. (Pubitemid 34451208)
34. Tickner JA, Schettler T, Guidotti T, McCally M, Rossi M. Health risks posed by use of di-2-ethylhexyl phthalate (DEHP) in PVC medical devices: a critical review. Am J Ind Med 2001; 39:100-11.
35. FDA public health notification: PVC devices containing the plasticizer DEHP Rockville (MD): U.S. Food and Drug Administration; 2002 Jul 12. Available from: http://www.fda.gov/cdrh/safety/dehp.html.